Search
Radiopharm Theranostics Ltd
RADXAdd to Watchlist
4.370USD
+0.100+2.34%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Radiopharm Theranostics Ltd Company
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Radiopharm Theranostics Ltd Info
Ticker SymbolRADX
Company nameRadiopharm Theranostics Ltd
IPO dateNov 25, 2021
CEOCanevari (Riccardo)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
AddressLevel 3, 62 Lygon Street
CityMELBOURNE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code3053
Phone61398245254
Websitehttps://radiopharmtheranostics.com/
Ticker SymbolRADX
IPO dateNov 25, 2021
CEOCanevari (Riccardo)
Company Executives of Radiopharm Theranostics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bruce Goodwin
Mr. Bruce Goodwin
Non-Executive Director
Non-Executive Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
FAQs
Who are the top five shareholders of Radiopharm Theranostics Ltd?
The top five shareholders of Radiopharm Theranostics Ltd are: Mr. Riccardo Canevari
How many institutions hold shares of Radiopharm Theranostics Ltd (RADX)?
As of 2026Q1, 11 institutions hold shares of Radiopharm Theranostics Ltd, with a combined market value of approximately 51.39M, accounting for 3.30% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 50862187.00.